Home
overview

This conference has already taken place.  For information on the 2010 event, please click on the link below:

 

COPD: Novel Therapeutics and Management Strategies 2010

 


For information about the 2009 COPD conference, please see below...

 

“Good interaction between delegates.”
Magnus Korsgren, Associate Professor Research Physician, Astrazeneca, Speaker, SMi’s Asthma & COPD Conference 2009
 

COPD is the fourth biggest killer in Europe, with mortality continuing to rise at a time when the mortality rates associated with cardiovascular diseases are declining.  Affecting up to 10% of adults COPD causes around 300,000 deaths in Europe every year.  With a strong link visible between smoking and development of the disease, smoking cessation is currently the only successful method to slow the worsening of the disease.  The drugs to manage the symptomes of COPD are often designed for use in asthma, meaning there are very few drugs developed for COPD alone.

SMi's 2009 COPD: Novel Therapeutics and Management Strategies conference aims to address the imbalance in research between Asthma & COPD, and place the spotlight firmly on COPD alone.  This conference will bring together industry experts to discuss the latest research developments in drug discovery and development, alongside the technological advancements in drug formulation and inhalation delivery methods.

This conference provides a much needed opportunity to focus on the challenges faced in the development of drugs for those suffering from COPD.

Key Benefits of Attending:

  • HEAR from leading researchers in the COPD field
  • DISCUSS novel therapeutics and the hopes for the future
  • LEARN about the important differences between Asthma & COPD, causing the need for unique therapies
  • DISCOVER the latest developments in inhalation technology for the treatment of COPD

Delegates at our Asthma & COPD conference this year included:

  • AstraZeneca, Director of Discovery Medicine
  • Imperial College, Professor of Thoracic Medicine
  • Kings College London, Professor
  • Synairgen, Head of Development
  • Astrazeneca R & D Lund, Associate Professor Research Physician
  • Boehringer Ingelheim, Vice President
  • Fibrex Medical Inc, VP, Research
  • Boehringer Ingelheim, Research & Development
  • GlaxoSmithKline, European Regulatory Affairs
  • Boehringer Ingelheim, Senior Scientific Adviser
  • Laboratorios Almirall, New Products Manager
  • Napp Pharmaceuticals, Brand Manager
  • Nycomed, Senior Scientist
  • Pfizer, Director, Senior Clinical Scientist
  • Sanofi-Aventis, Head of Marketing
  • Syntaxin, Head of DiscoveryZambon Spa, Product & Technology Discovery Manager
  • Astrazeneca R & D Lund, Associate Professor Research Physician
  • Imperial College Faculty of Medicine, Chair in Acute Medicine
  • Novartis International, Head of Global Advocacy
  • Topigen Pharmaceuticals, Chief Executive Officer
  • Biotie Therapies, VP Inflammatory Disease Area
  • Boehringer Ingelheim, Vice President
  • GlaxoSmithKline, Senior Regulatory Scientist
  • Boehringer Ingelheim, Senior Research Physician
  • Medimmune, Senior Research Scientist
  • Napp Pharmaceuticals, Area Sales Manager
  • National University Of Singapore, Associate Professor
  • Pacific Northwest National Laboratory, Director, Facilities for Systems Biology & Applications
  • Synairgen, Managing Director
  • UCB Belgium, VP, Clinical Research Immunology
  • Chiesi Farmaceutici, Head of Corporate Clinical Development
  • Imperial College School of Medicine (N.H.L.I.), Professor of Adult Respiratory Medicine
  • Novartis Pharmaceuticals, Principal Scientist
  • UCB-Celltech, Senior Scientist
  • Boehringer Ingelheim, Clinical Monitor, Project Manager
  • Genentech, Senior Clinical Scientist Specialist
  • Boehringer Ingelheim, Medical Adviser
  • Hydra Biosciences, Chief Scientific Officer
  • Laboratorios Almirall, Clinical Trial Manager
  • Merck Sharp & Dohme, Regulatory Affairs Manager
  • Nycomed Belgium, Medical Director
  • Pfizer, Daphne Jackson Fellow (Post Doc)
  • Sanofi Aventis, Researcher
  • Syntaxin, Clinical Research Scientist
  • Vectura, Development Director

 

Conference programme

9:00 Registration & Coffee

9:30 Chairman's Opening Remarks

Dirk Bredenbroeker

Dirk Bredenbroeker, Executive Director of European Medical Research, Mundipharma Research

9:40 TREATMENT OF COPD TODAY - WHAT ARE OUR OPTIONS IN 2009?

Dirk Bredenbroeker

Dirk Bredenbroeker, Executive Director of European Medical Research, Mundipharma Research

  • What the GOLD treatment guidelines tell us to do
  • The role of ICS/LABA combination treatment in the current armamentarium - what clinical evidence is available?
  • Treatment with LAMAs and potential for triple combinations
  • 10:20 BIOLOGICAL APPROACHES TO COPD

    Donna Finch

    Donna Finch, Head of Biology, Respiratory, Inflammation and Autoimmunity, Medimmune

  • Targets for biologicals
  • Development challenges associated with biologicals for COPD
  • The future for biologicals
  • 11:00 Morning Coffee

    11:40 THE NEED FOR A UNIQUE APPROACH

    Robert Stockley

    Robert Stockley, Director of R&D and Consultant Physician , University Hospital Birmingham NHS Trust

  • The treatment of COPD is often undertaken with drugs developed primarily for the treatment of Asthma
  • With COPD a different disease to Asthma these are often not the most targeted therapies
  • There is therefore a need to consider COPD separately and develop specific drugs for treatment
  • 12:20 LINK TO HEART DISEASE

    Rudolf Jörres

    Rudolf Jörres, , University Of Munich

  • Impact of heart disease in COPD
  • Anticholinegics and heart disease
  • Use of statins
  • 13:00 Networking Lunch

    14:30 REDUCING EXACERBATIONS IN COPD: RATIONALE AND EMERGING APPROACHES USING MAINTENANCE INHALED ANTIMICROBIALS

    Michael Dudley

    Michael Dudley, Senior VP Research & Development & Chief Scientific Officer, Mpex Pharmaceuticals

  • Role of chronic bacterial infections and exacerbations in COPD
  • Lessons learned from the management of chronic pulmonary infections in cystic fibrosis
  • Approaches for management of chronic pulmonary infections in COPD, including use of aerosol antimicrobial agents
  • 15:10 TREATING AUTO-IMMUNITY IN COPD

    Matthew Catley

    Matthew Catley, Senior Scientist, UCB-Celltech

  • Smoking and autoimmune disease
  • The evidence that  autoimmunity is involved in COPD
  • Treating autoimmunity may provide novel targets in COPD
  • 15:50 CLINICAL OUTCOMES

    Tim Higenbottam

    Tim Higenbottam, Head of Corporate Clinical Development , Chiesi Farmaceutici

  • Difficult to relate biomarkers to clinical outcomes
  • Predicting disease progression
  • Indicating disease instability
  • Predicting response to therapy
  • 16:30 Chairman’s Closing Remarks

    16:40 Afternoon Tea and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Frank Thielmann

    Frank Thielmann, Senior Fellow, PDU Inhalation, Novartis Pharmaceuticals

    9:10 ANIMAL MODELS IN COPD

    Jonathan Phillips

    Jonathan Phillips, Principal Scientist, Respiratory Drug Discovery, Schering Plough

  • COPD related pathologies that can be reproduced in mouse models and limitations
  • Gene chip microarray studies for new target mining and understanding if mouse-models are an effective tool for COPD drug efficacy prediction
  • Identification of mechanisms of disease progression in acute, sub-chronic and chronic smoke exposure models
  • Strengths of mouse model versus other rodents
  • Anti-inflammatory drugs evaluated in acute mouse-model example
  • 9:50 THE POTENTIAL OF SELECTIVE iNOS INHIBITORS FOR COPD

    Christian Hesslinger

    Christian Hesslinger, Associate Director and Head of In-Vitro Biology, Nycomed

  • Identification of selective oral iNOS inhibitors for the treatment of COPD
  • Efficacy of several oral iNOS inhibitors in a 11-day smoke mouse model (inflammatory cellinflux and cytokine production)
  • Discussion of advantages and limitations of the smoke mouse model used focusing on iNOS inhibitors
  • 10:30 Morning Coffee

    11:00 VAPOURS, GASES, POWDERS AND PROPELLANTS

    Mark Sanders

    Mark Sanders, , Inhalatorium

  • Discover the pioneers of inhalation therapy
  • Key innovations that have moved science forward
  • Enduring challenges for inhalation
  • 11:40 DEVELOPING MODELS OF ACUTE EXACERBATIONS OF COPD

    Elizabeth Hardaker

    Elizabeth Hardaker, Research Investigator 1, Novartis

  • Enhanced inflammation during acute exacerbations of COPD - data from the clinic
  • Modelling viral induced exacerbations
  • Modelling bacterial induced exacerbations
  • 12:20 Networking Lunch

    13:50 RELEVANCE OF PHYSICO-CHEMICAL PROPERTIES FOR THE DEVELOPMENT OF INHALED THERAPIES

    Frank Thielmann

    Frank Thielmann, Senior Fellow, PDU Inhalation, Novartis Pharmaceuticals

  • Key parameters of drug substance/ drug product affecting stability and in vitro / in vivo performance
  • Characterisation methods for the determination and monitoring of these parameters
  • Understanding of formulation-device interations
  • Quality by Design aspects
  • 14:30 SMART DEVICE/FORMULATION COMBINATIONS FOR AN EFFICIENT TREATMENT OF COPD

    Fadi Eskandar

    Fadi Eskandar, Fellow, Pharmaceutical Development Unit Inhalation, Novartis Pharmaceuticals

  • Driving forces for inhalation development
  • New devices coming to the market
  • Performance optimisation
  • 15:10 REGULATORY & CLINICAL REQUIREMENTS IN GENERIC INHALATION THERAPIES FOR COPD

    Anders Fuglsang

    Anders Fuglsang, Clinical & Regulatory Strategy Manager, Aeropharm

  • New EU-guideline in force
  • The stepwise approach to proving product similarity
  • In vitro similarity: flow rate vs. pressure drop
  • Role of PK and PD studies
  • Extrapolation from Asthma to COPD
  • 15:50 Chairman’s Closing Remarks

    16:00 Afternoon Tea and Close of Conference

    +

    Workshops

    Le Méridien

    Bayerstrasse 41
    Munich Bavaria 80
    Germany

    Le Méridien

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.